ArticlePloS one2013
Alterations in gene expression of proprotein convertases in human lung cancer have a limited number of scenarios.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- PCSK5 downregulation promotes the inhibitory effect of andrographolide on glioblastoma through regulating STAT3.Molecular and cellular biochemistry · 2025Article
- Review
- PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity.Journal of experimental & clinical cancer research : CR · 2023Article
- Review
- Inactivation ofCancer research communications · 2022Article
- Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.World journal of surgical oncology · 2022Article
- Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- Transcriptomic Profiling of Gene Expression Associated with Granulosa Cell Tumor Development in a Mouse Model.Cancers · 2022Article
- Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker.Frontiers in molecular biosciences · 2021Article
- A five-mRNA signature associated with post-translational modifications can better predict recurrence and survival in cervical cancer.Journal of cellular and molecular medicine · 2020Article
- Article
- Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.Cell cycle (Georgetown, Tex.) · 2019Article
- Up-regulation of PCSK9 gene expression and diminished level of LDL-receptor in rat liver as a potential cause of post-lipectomy hypercholesterolemia.Molecular and cellular biochemistry · 2019Article
- Autoencoder Based Feature Selection Method for Classification of Anticancer Drug Response.Frontiers in genetics · 2019Article
- A transcriptome-based protein network that identifies new therapeutic targets in colorectal cancer.BMC genomics · 2017Article
- Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia.BMC medical genetics · 2017Article
- Targeting proprotein convertases in furin-rich lung cancer cells results in decreased in vitro and in vivo growth.Molecular carcinogenesis · 2017Article
- An activated form of ADAM10 is tumor selective and regulates cancer stem-like cells and tumor growth.The Journal of experimental medicine · 2016Article
- [MiR-373-3p Promotes Invasion and Metastasis of Lung Adenocarcinoma Cells].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2015Article
- MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proprotein convertases (PCs) is a protein family which includes nine highly specific subtilisin-like serine endopeptidases in mammals. The system of PCs is involved in carcinogenesis and levels of PC mRNAs alter in cancer, which suggests expression status of PCs as a possible marker for cancer typing and prognosis. The goal of this work was to assess the information value of expression profiling of PC genes. Quantitative polymerase chain reaction was used for the first time to analyze mRNA levels of all PC genes as well as matrix metalloproteinase genes MMP2 and MMP14, which are substrates of PCs, in 30 matched pairs of samples of human lung cancer tumor and adjacent tissues without pathology. Significant changes in the expression of PCs have been revealed in tumor tissues: increased FURIN mRNA level (p<0.00005) and decreased mRNA levels of PCSK2 (p<0.007), PCSK5 (p<0.0002), PCSK7 (p<0.002), PCSK9 (p<0.00008), and MBTPS1 (p<0.00004) as well as a tendency to increase in the level of PCSK1 mRNA. Four distinct groups of samples have been identified by cluster analysis of the expression patterns of PC genes in tumor vs. normal tissue. Three of these groups covering 80% of samples feature a strong elevation in the expression of a single gene in cancer: FURIN, PCSK1, or PCSK6. Thus, the changes in the expression of PC genes have a limited number of scenarios, which may reflect different pathways of tumor development and cryptic features of tumors. This finding allows to consider the mRNAs of PC genes as potentially important tumor markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.